Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05033756
Title Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO (COMPRENDO)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Institut fuer Frauengesundheit
Indications

Her2-receptor negative breast cancer

Therapies

Olaparib + Pembrolizumab

Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
Department of Gynecology, Tübingen University Hospital Tübingen Baden-Württemberg 72076 Germany Details
University Hospital Ulm Ulm Baden-Württemberg 89075 Germany Details
Department of Gynecology and Obstetrics, Erlangen University Hospital Erlangen Bavaria 91054 Germany Details
Marienhospital Bottrop Bottrop North Rhine Westphalia 46236 Germany Details
University Hospital Düsseldorf Düsseldorf North Rhine Westphalia 40225 Germany Details
Helios-Klinikum Berlin-Buch Berlin 13125 Germany Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field